r Motoneuron soma size is a largely plastic property that is altered during amyotrophic lateral sclerosis (ALS) progression.
Introduction
Neurons within the central nervous system vary widely in size, and this variation has functional significance for the neuron's behaviour. Studies in spinal alpha-motoneurons (α-motoneurons) have established that the size of the motoneuron correlates proportionally with the cell's fibre diameter, number of innervated muscle fibres, and motor unit size (Burke & Tsairis, 1973; Cullheim & Ulfhake, 1979; Chamberlain & Lewis, 1989; Rafuse et al. 1997) . Accordingly, small motoneurons (S-type) have the smallest cell and motor unit sizes, lowest force magnitude, and slowest contractile dynamics, whereas large motoneurons (F-type) have the largest cell and motor unit sizes, highest force magnitude, and fastest contractile dynamics. The size of the motoneuron also correlates inversely with the cell's excitability, discharge behaviour, and firing rate (Henneman, 1957; Henneman et al. 1965) . Because of these properties, motoneurons are recruited in the order of their size (i.e. small cells are recruited first followed by large cells) during movement (the size principle, Henneman, 1957) . Therefore, neuronal size has a significant impact on the physiological function of the neuron.
One important question that remains is whether α-motoneuron size is a plastic or fixed property. More specifically, does the cell size, and especially the soma size, change depending on the conditions that it experiences? Although it might constitute only a small proportion of the total cell size, the soma size has a strong impact on the motoneuron excitability and is dynamically tied to the cell's metabolic and energy needs as well as to the overall motor unit size. A theory, therefore, was extended in favour of soma size plasticity in spinal motoneurons (Krishnan, 1983) predicting that the soma size of the motoneuron plastically changes during neuronal development, injury and disease states. While motoneuron soma size plasticity has been extensively studied in development (Baulac & Meininger, 1983; Prakash et al. 2000) and after injury (Barr & Hamilton, 1948; Donselaar et al. 1986; Vanden Noven et al. 1993; Bose et al. 2005) , less attention has been given to possible soma size plasticity in disease pathogenesis.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease in which motoneurons degenerate. Furthermore, their vulnerability is interestingly proportional to their size: Degeneration of larger, fast-type α-motoneurons is followed by that of smaller, slow-type α-motoneurons (Pun et al. 2006; Hegedus et al. 2007 Hegedus et al. , 2008 Saxena et al. 2013) . Motoneuron populations spared in the disease (e.g. gamma and oculomotor motoneurons) are generally smaller in size than those vulnerable in the disease (e.g. lumbar and hypoglossal motoneurons) (Friese et al. 2009; Shoenfeld et al. 2014) . Importantly, this size-associated motoneuron vulnerability is similar in both familial and sporadic ALS (Shaw et al. 1997) , indicating that this motoneuron vulnerability differential is independent of the cause of the disease, but rather is likely to be due to factors intrinsic to the motoneuron that render the cell more or less susceptible to toxic events. One, therefore, might speculate whether motoneuron size underlies this vulnerability differential, and whether motoneurons change their size in the disease in a way that renders them more or less vulnerable. Morphological studies have reported conflicting data on the size change of mutant motoneurons in several transgenic mouse models of ALS (Amendola & Durand, 2008; Filipchuk & Durand, 2012; Leroy et al. 2014; Shoenfeld et al. 2014) . Mouse models also offer conflicting results when compared with human data from ALS patients (Kiernan & Hudson, 1991) . However, none of these studies have tracked the motoneuron size changes throughout the disease process in order to examine potential long-term patterns in size changes during disease pathogenesis. This information is critical because identification of cell protection and vulnerability mechanisms might provide information on disease pathogenesis and lead to treatments that can prevent the progressive death of motoneurons. For instance, it would be important to determine whether motoneurons exhibit consistent soma size changes throughout the disease process. Furthermore, do disease-resistant motoneurons (i.e. S-type) exhibit soma size changes differently from the more disease-vulnerable motoneurons (i.e. F-type)? Is the motoneuron size change a disease mechanism (i.e. a stressor) that contributes to the disease pathogenesis or a compensatory mechanism (i.e. an ameliorating mechanism) that helps motoneurons restore their excitability state? These answers could additionally help us to understand how motoneuron size changes contribute to the process of excitability regulation of disease-resistant and disease-vulnerable motoneurons.
To address these questions, we measured α-motoneuron soma sizes throughout the lifespan of mutant mice in the G93A transgenic line. Four time points were examined (postnatal days 10, 30, 90 and at end stage) which correspond to different stages in disease pathogenesis. Our results show that α-motoneurons exhibit soma size changes with a time-dependent pattern (i.e. early enlargement, followed by no change, then shrinkage) during the disease process. When the soma size of disease-vulnerable versus disease-resistant motoneurons was compared, we also show, for the first time, a relationship between the vulnerability of motoneurons and their soma size change. Specifically, disease-vulnerable motoneurons were found to increase their soma size, whereas disease-resistant motoneurons either reduced or did not change -but did not increase -their soma size. This plasticity differential between disease-vulnerable and disease-resistant motoneurons was confirmed across spinal cord regions, genders and motoneuron types. When examined in computer simulations, the measured changes in soma size were found to have profound effects on the excitability of disease-vulnerable and disease-resistant motoneurons. These results provide novel information on the plasticity of cellular changes in size that both disease-vulnerable and disease-resistant motoneurons experience during the disease, as well as how these size changes relate, and might contribute, to cell survival.
Methods

Ethical approval
All animal procedures were performed in accordance with the regulations of the Wright State University Laboratory Animal Care and Use Committee (LACUC) and also in accordance with the laws of the United States of America (under animal protocol numbers 1010 and 1046). Care was taken to minimize pain and distress at all times. The authors understand the ethical principles under which this journal operates and this work complies with those guidelines. No human subjects were involved in this study.
Animal models
All mice were either purchased from The Jackson Laboratory or bred from these purchased mice, to produce male mice with a B6SJL-TG genetic background (Tg(SOD1 * G93A)1Gur). Briefly, B6/SJL hybrid females (Stock no. 100012) were bred with male hemizygote mice (Stock no. 004435) expressing the human SOD1 gene with a glycine-to-alanine mutation at amino acid 93 (SOD1-G93A). This mouse model was chosen because it is well documented and displays an aggressive form of ALS, which can make disease changes easier to detect. Transgenic, non-carrier (WT) littermates were used as controls. For MMP9/SK3 co-labelling experiments (Fig. 9 ), WT and non-transgenic (WT nt ) adult male mice (B6/SJL; The Jackson Laboratory, Bar Harbor, ME, USA), 120-130 days old, were used. Food and water were available ad libitum.
Male and female offspring of this pairing were used for all experiments, except where noted, and compared with their non-carrier littermates (WT). Genotyping using tail clippings was performed by Transnetyx, Inc. All mutant hemizygous mice expressed a high copy number of the mutated gene (>25 copies). Mutant mice and their non-carrier littermates were killed at four time points: Postnatal day 10 (P10), P30, P90 and end-stage (ES; predefined as full hindlimb paralysis, usuallyßP120-P140).
Terminal procedures
All animals were anaesthetized intraperitoneal with a lethal dose of Euthasol solution (150 mg kg −1 , pentobarbital sodium and phenytoin sodium). Once the reflexive response, measured via toe pinch, was absent the animal was transcardially perfused with vascular rinse (0.01 M phosphate buffer with 0.8% NaCl, 0.025% KCl, and 0.05% NaHCO 3 , pH 7-8), followed by 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7-8. This is a terminal procedure as the animal is exsanguinated and spinal cord removed.
Tissue preparation
The following segments of the spinal cord were used in this study: lower lumbar (L4-L6), cervical (C2-C5), and sacral (S1-S3). These segments were quickly removed and post-fixed in 4% paraformaldehyde fixative for ß2 h or overnight. Tissue was then stored in 15% sucrose at 4°C overnight. Coronal spinal sections were then cut on a cryostat at a thickness of ß50 μm. Floating sections were randomly collected for further processing and stored in 0.01 M PBS, pH 7-8.
Spinal cord immunohistochemistry
Sectioned spinal cord segments were stained with antibodies for vesicular acetylcholine transporter (VAChT; 1:1000 dilution; goat, Abcam Inc, Cambridge, MA, USA; RRID: AB 956453), for voltage-gated potassium channel subfamily B member 1 (Kv2.1; 1:1000 dilution; mouse, NeuroMab, Davis, CA, USA; 76-014), and, where appropriate, for calcium-activated potassium channel subfamily N member 3 (SK3; 1:1000 dilution; rabbit, Millipore, Billerica, MA, USA; AB5350). The antibodies for MMP9/SK3 co-labelling experiments were matrix metalloproteinase 9 (MMP9; 1:1000 dilution; goat, J Physiol 596.9 Sigma-Aldrich, St. Louis, MO, USA; M9570), VAChT (1:1000 dilution, mouse, Abcam ab134298), SK3 (1:1000 dilution; rabbit, Millipore) and Neuronal nuclei (NeuN; 1:300 dilution; guinea-pig, Sigma ABN90).
Sections were rinsed with PBS-T (0.01 M PBS containing 0.1% Triton-X, pH 7.3), blocked with normal horse serum (10% in PBS-T), and then incubated free-floating in cocktails of primary antibodies overnight at 4°C. All antibodies were diluted with PBS-T. Nissl immunocytochemistry was performed using a 435/455 blue fluorescent Nissl stain (1:100; catalogue no. N-21479, Neurotrace, Life Technologies, Carlsbad, CA, USA) to visualize cell bodies. All primary antibodies were diluted in PBS-T 0.1%, pH 7.4, and incubated overnight at 4°C.
Immunoreactivity was detected with an assortment of rabbit, guinea-pig, mouse, and goat-specific secondary antibodies conjugated to Cy3 and Alexa Fluors 488, 405 and 647 (Jackson ImmunoResearch, West Grove, PA, USA), respectively, diluted 1:50 in 0.1% PBS-T, pH 7.4, and incubated at room temperature for ß3 h. Sections were then mounted randomly onto slides and cover-slipped in Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA).
Confocal microscopy and morphometric analysis
Images of spinal motoneurons for 2-dimensional morphometric analysis were obtained in 1 or 2 μm steps on a Fluoview 1000 (Olympus) confocal microscope with a 20× dry objective. α-Motoneurons were differentiated on the basis that largest cross-sectional area (LCA) measurements fell within a previously published range of >300 μm 2 (Ishihara et al. 2013) , that they were located in Rexed lamina IX and had a visible nucleolus, and that they received synaptic input from large cholinergic boutons and/or expressed large Kv2.1 clusters, as evidenced by VAChT and Kv2.1 immunoreactivity (VAChT-IR and Kv2.1-IR). In type-based analysis, SK3 immunoreactivity was used to identify α-motoneurons as either fast (SK3 negative) or slow (SK3 positive), as described by others (Deardorff et al. 2013) . For a subset of the experiments establishing size ranges for α-motoneuron types ( Fig. 9E and F) , MMP9 and NeuN immunoreactivity were additionally used to delineate three groups of α-motoneurons: (1) MMP9 positive, SK3 negative, (2) MMP9 negative, SK3 negative and (3) MMP9 negative, SK3 positive cells. Cells that exhibited dual immunoreactivity (SK3 positive, MMP9 positive) were excluded from further analysis, as they composed a very small percentage of the total population (<5%).
The entirety of motor pools within a slice was imaged, and care was taken to include all cells that met the criteria mentioned above. The authors are confident, with the stringency of this criteria, that they were able to restrict their analysis to only spinal α-motoneurons, and that they were able to include the full range present in the mouse spinal cord. Only images with cells that clearly demonstrated VAChT-IR and Kv2.1-IR, and NeuN-IR in the size range experiments of Fig. 9 , were used for analysis.
Images for 3-dimensional morphometric analysis were obtained on a Fluoview 1000 (Olympus) confocal microscope with a 60× oil-immersion objective in 1 μm steps. α-Motoneurons were differentiated on the basis that surface area measurements exceeded 1200 μm 2 , providing an equivalent diameter cutoff to the LCA measurements. Location in Rexed lamina IX and expression of VAChT and Kv2.1 immunoreactivity or NeuN immunoreactivity (size range experiments in Fig. 9 ) were also included as criteria.
For 2D analysis of motoneurons, images were loaded into Olympus Fluoview software, and regions of interest were drawn around the largest cross-sectional area (containing the nucleoli) of every identified motoneuron. Motoneurons without visible nucleoli or with LCAs smaller than <300 μm were not included in analysis.
At least two spinal cord slices per animal were analysed from three to five animals in every experimental and control group. The largest cross-sectional area measurements were recorded along with the total number of α-motoneurons obtained from each slice. Cell density measurements were obtained by dividing the total number of α-motoneurons by the measured thickness of the slice in Fluoview. Care was taken to include all α-motoneurons on all analysed images, so as to minimize bias in the selection of cells.
For measured 3D analysis of motoneurons, images were loaded into ImagePro Premier 3D software (Media Cybernetics, Rockville, MD, USA), and motoneuron somas were reconstructed using the isosurface tool. The pre-processing and 3D analysis of motoneurons was blinded to minimize bias, as described in our previous work (Dukkipati et al. 2017) , and thresholds were approximated by eye. At least two spinal cord slices per animal were analysed from three to five animals in every experimental and control group. The surface area and volume measurements were recorded from every reconstructed motoneuron.
In order to compare the 2D measured data to the 3D measured data, conversion of the 2D data was needed to estimate the soma 3D volume. The largest somatic cross-sectional area was then used to estimate the motoneuron volume using the following formulas from Zwaagstra and Kernell's study (Zwaagstra & Kernell, 1981) :
∧ 3, where r = radius of the motoneuron and v = estimated volume of motoneuron; r = (LCA/π), where LCA = measured largest cross sectional area of motoneuron.
Statistical analysis
Statistical analyses were experimental, not descriptive; random sampling was performed with both random selection of slices for staining and imaging, as described above. (Skovlund & Fenstad, 2001) . Significance for all tests was set at P < 0.05.
Computer simulations
To assess the effect of soma size changes on motoneuron excitability, we used a previously-published anatomically-detailed computer model of spinal α-motoneurons (Elbasiouny et al. 2005) . This model includes the somatic and dendritic voltage-gated ion channels that mediate action potentials in spinal motoneurons and has been previously verified and extensively used to study the firing behaviour and excitability of spinal motoneurons (Elbasiouny et al. 2005 (Elbasiouny et al. , 2006 Elbasiouny & Mushahwar, 2007a, b; Elbasiouny, 2014) . In these simulations, the soma size of the model motoneuron was varied and the motoneuron excitability was assessed from the gain and shape of the frequency-current (F-I) relationship measured in response to somatic current ramp injection.
Results
Spinal α-motoneuron identification in WT and G93A mice
In order to characterize soma size differences in spinal α-motoneurons during disease pathogenesis, we measured and compared the soma size of male WT and mutant G93A α-motoneurons at four time points: P10, P30, P90, and end-stage (ES). Males were used because males are more vulnerable than females in ALS (McCombe & Henderson, 2010) . The four time points measured correspond to important stages of disease pathogenesis. At P10, the earliest cellular motoneuron abnormalities have been observed in the G93A model, yet neurodegeneration has not started (Quinlan et al. 2011; Leroy et al. 2014) . At P30, degeneration of large motoneurons (the more vulnerable population) commences whereas degeneration of small motoneurons (the more resistant population) begins around P90 (Hegedus et al. 2007 (Hegedus et al. , 2008 Saxena et al. 2013) . At ES, mutant G93A mice have developed full paralysis of both hindlimbs and fail to right themselves, at which point the animals are killed. This usually occurs between P120 and P140 in this model. Spinal α-motoneurons were identified using the combination of VAChT, Kv2.1, and Nissl labelling, and their sizes were assessed by measuring their largest somatic cross-sectional areas (see Methods). Figure 1 shows representative images of tissue from WT and mutant G93A mice, with labelling of pools of α-motoneurons. The coefficient of variation in the soma size data was calculated and compared at all four time points among WT and mutant G93A animals in Table 2 . We confirmed that variance in the soma size distributions within animals was little and comparable (0.24-0.39 for WT vs. 0.24-0.45 for G93A).
Somatic enlargement in early disease pathogenesis
We first examined soma size changes in the early disease stages of male mutant G93A mice at P10 and P30. Our data show that G93A motoneurons at these neonatal and young adult time points had a significant increase in average soma size relative to WT motoneurons ( Fig. 2 , Table 1 , P < 0.01 and P < 0.0001, respectively). However, when the data were compared in relative and cumulative frequency histograms, the proportion of motoneuron subgroups appeared to be affected differently in the disease. Specifically, at P10 the proportion of mid-size motoneurons (600-800 μm 2 ) showed some decrease, the proportion of large motoneurons (>1200 μm 2 ) showed some increase, whereas the proportion of small motoneurons (<600 μm 2 ) did not change ( Fig. 3A and B; additional analysis is provided in Figs 8 and 9). It is important to mention that motoneuron degeneration has not started yet at the very early P10 age. A similar, but . In a subset of tissue, we were able to use SK3 labelling in order to identify motoneuron types in WT (A) and G93A mice (E). Depicted in white arrows are identified motoneurons that are visualized in the higher magnification insets. Scale bar in D applies to all panels. more notable, somatic enlargement shift was observed in all motoneurons at P30, indicated by a rightward shift in the G93A data relative to WT ( Fig. 3C and D) . We also detected a significant decrease in the proportion of small and mid-size motoneurons (<800 μm 2 ) which was accompanied by a significant increase in the proportion of large motoneurons (>800 μm 2 ; additional analysis is provided in Fig. 9 ).
Additionally, while WT motoneurons showed a larger soma size range at P30 than P10, reflecting the normal developmental process (blue dots in Fig. 3E ), we observed that G93A motoneurons showed the opposite, with an apparently smaller range at P30 than P10 (red dots in Fig. 3E ).
Reversal in soma size changes in late disease pathogenesis
We then examined soma size changes in the mid (P90) and late (ES) disease stages of male mutant G93A mice. Surprisingly, the somatic enlargement observed in G93A motoneurons in the early disease stages disappeared and G93A motoneurons exhibited comparable soma size to WT motoneurons at P90 (Fig. 2, Table 1 ). A closer look at the relative frequency and cumulative frequency histograms of small versus large motoneurons indicated insignificant changes between WT and G93A motoneurons at that age (Fig 4A and B) . At ES, interestingly, G93A motoneurons reversed their soma size change pattern and exhibited a massive reduction in their soma size (by ß40%) relative to WT (Fig. 2 , Table 1 , P < 0.0001). At that disease stage, the vast majority of large motoneurons and many mid-size motoneurons have degenerated; however, it was interesting to observe that surviving motoneurons showed a significantly higher proportion of cells with small soma size (Fig 4C and D) . 
Confirming soma size differences using 3D reconstructions
One may argue that the assessment of soma size in Figs 2-4 was based on 2-dimensional morphometric analysis and that 3-dimensional analysis might offer more accurate and differing results. To address this possibility, we conducted a more-detailed 3D morphometric analysis on a subset of our data and compared the 3D data to the 2D data measured from the same tissue. Specifically, we prepared 3D reconstructions of identified WT and G93A α-motoneurons at P30, measured their soma volume, and compared these volumes to the somatic largest cross-sectional areas of cells at the same time point. The results (Table 3) showed similar relative ranges and distributions for the volume and largest cross-sectional area measurements at P30 (for relative ranges, compare Fig. 5A to the P30 data in Fig. 3E ; for the largest cross-sectional area, compare Fig. 5B to Fig. 3C) . The volume measurements also demonstrated a similar shift in cell size in the G93A motoneuron distribution relative to WT cells (Fig. 5B) . Importantly, the volume measurements also showed a significant increase in soma size of G93A motoneurons relative to WT cells (Fig. 5C , first two bars), replicating the largest cross-sectional area data presented in Fig. 2 . In fact, the percentage increase in 3D volume data (13.4%, Table 3 ) was comparable to that of the 2D largest cross-sectional area data (15.9%, Table 3 ) between G93A and WT motoneurons (Fig. 5D) .
In a second set of analyses, we converted our 2D measurements into 3D measurements using previously published formulas (Zwaagstra & Kernell, 1981) . Specifically, we used the largest cross-sectional area measurement in order to estimate the motoneuron volume using the formulas proposed by Zwaagstra and Kernell (see Methods). Interestingly, the estimated volume data were in general much higher, for both WT and G93A motoneurons, than the actual volume data obtained from reconstruction, indicating a significant overestimation (by 88% and 116%, respectively; Fig. 5C , Table 3 ). However, comparison of the estimated volumes still showed that G93A motoneurons are enlarged relative to WT cells (Fig. 5C , second set of bars).
Taken collectively, the 3D results confirmed the accuracy of our 2D morphometric analyses and support our earlier conclusions.
Generality of soma size changes in G93A motoneurons -regional analysis
Our data so far have supported the idea that motoneuron soma size is a plastic property with a time-dependent pattern (i.e. early enlargement, followed by stability or no change, then shrinkage) during the disease process (Fig. 2) . However, it is unclear whether these soma size changes are universal or specific to the lumbar spinal cord region. Additionally, it is unclear whether similar soma size plasticity is expressed by disease-resistant motoneurons and/or by motoneurons that are more vulnerable. To answer these questions, we examined whether soma size differences also exist in other regions of the spinal cord. At P30, we examined the soma size of motoneurons in the cervical and sacral spinal regions and compared this data to our measurements of motoneurons in the lumbar region. These spinal regions were chosen for this analysis because motoneurons in those regions have different vulnerability levels in the disease, with locomotive motor impairments (mediated by lumbar motoneurons) occurring early, followed by tail impairments (mediated by sacral motoneurons, (Alves et al. 2011) ), then respiratory failure (mediated by cervical motoneurons) occurring later in the disease (Llado et al. 2006; Smittkamp et al. 2010) . P30 was chosen for this analysis because it is an early adult time point with minimal neurodegeneration in any spinal region. Figure 6 shows soma LCA differences between WT and G93A motoneurons at P30 in the cervical, lumbar and sacral spinal regions. Interestingly, we found different soma size patterns among these spinal regions. Relative to WT cells, G93A lumbar motoneurons (the more vulnerable population) expressed somatic enlargement, G93A sacral motoneurons expressed no changes in soma size, and G93A cervical motoneurons (the less vulnerable population) expressed somatic shrinkage (Fig. 6A , Table 4 ). Comparing the distribution of motoneurons, cervical motoneurons exhibited a leftward shift in their histogram indicating a higher proportion of the smallest size motoneurons (LCA between 300 and 700 μm 2 , Fig. 6C, left panel) , which is opposite to the rightward shift exhibited by lumbar motoneurons indicating a lower proportion of the smallest size motoneurons (Fig. 6C,  middle panel) . No apparent changes were observed in the distribution of G93A motoneurons in the sacral region relative to WT cells (Fig. 6C, right panel) . Additionally, cervical G93A motoneurons had a much smaller size range than lumbar and sacral motoneurons (Fig. 6B) .
In sum, the results of the regional analysis confirmed that changes in soma size of G93A motoneurons are not specific to the lumbar cord and exist in other spinal segments; however, these changes have different directions (i.e. increased soma size in lumbar motoneurons but decreased soma size in cervical motoneurons). The analysis also showed a trend between the vulnerability of motoneurons and their soma size changes. Specifically, motoneurons located in segments more vulnerable to the onset of disease exhibit an increase in soma size (e.g. lumbar motoneurons), whereas motoneurons located in segments more resistant to disease onset either do not change (e.g. sacral motoneurons) or decrease (e.g. cervical motoneurons) in soma size. The next section examines these emerging trends in more detail.
Soma size plasticity in G93A motoneurons -gender analysis
In order to investigate whether a relationship exists between the vulnerability of α-motoneurons and their soma size changes, we examined the soma size of lumbar motoneurons between males and female mice at P10, an early time point at which motoneuron cellular properties have just started to change. The incidence and prevalence of ALS, in patients and G93A mice, is increased in males vs. females (McCombe & Henderson, 2010) . Interestingly, G93A lumbar motoneurons from females did not exhibit an increase but exhibited a decrease in soma size, relative to WT, as opposed to G93A lumbar motoneurons from males who exhibited an increase in soma size (Fig. 7A , Table 5 ). The histogram of female motoneurons showed a leftward shift in soma size indicating a higher proportion of smaller motoneurons than in the male animals. Comparing the ranges, we found that both male and female motoneurons in WT mice had similar soma sizes (Fig. 7D, blue dots) , but noted a reversal in soma size changes in mutant G93A motoneurons in female compared to male mice (Fig. 7D, red dots) . We also saw that the expansion in soma size range in G93A motoneurons in male mice did not exist in female mice ( Fig. 7D ; see the dotted box). Also, the increase in the largest motoneurons (LCA > 1200-1500 μm 2 ) that we observed in male mutant G93A mice was not seen in their female counterparts.
Collectively, these data support the notion that an increased soma size is only observed in disease-vulnerable motoneurons.
Soma size plasticity in G93A motoneurons -cell type analysis
To further test the hypothesis that a relationship exists between the vulnerability of α-motoneurons and their soma size plasticity, we split motoneurons into their respective types (S vs. F types) and compared soma size changes in the disease-vulnerable F population versus the disease-resistant S population. Because S type motoneurons express SK3 immunoreactivity and F type motoneurons do not (Deardorff et al. 2013) , we used SK3 immunostaining to label S type motoneurons (indicated as SK3 positive cells, SK3 + in Fig. 8 ) versus F type motoneurons (indicated as SK3 negative cells, SK3 − in Fig. 8 ). The soma size changes between G93A and WT motoneurons for the two types were examined at both P10 and ES, in order to examine soma plasticity when neurodegeneration is in its initial stage and at its full magnitude, respectively.
Our results (see the statistical analysis in Table 6 ) show that the earliest motoneuron somatic changes at P10 started in, and were limited to, the more vulnerable F type motoneurons and were expressed as somatic enlargement (Fig. 8A, filled bars) ; whereas the resistant S type motoneurons did not exhibit any somatic changes (Fig. 8A,  hashed bars) . This indicates that the enlargement of F motoneurons noted here drove the overall enlargement noted in Fig. 2 at P10 . No evidence of cell death was noted in either motoneuron type at that early stage of the disease, as indicated by a lack of statistically significant differences in the density of cells per unit tissue volume (Fig. 8B ) and the proportions (Fig. 8C ) between G93A and WT mice. Conversely, at ES, the picture was entirely different. Both motoneuron types exhibited statistically significant shrinkage in their soma sizes (Fig. 8D) , as well as changes in their proportions (the proportion of the S type increased, whereas the proportion of the F type decreased, Fig. 8F ). One potential explanation for these changes is that cell death underlies this shrinkage in soma size and the alteration in cell type proportions. However, the absence of differences in the S type cell density but reduction in the F type cell density between G93A and WT mice supports the existence of cell death only in the F type, explaining the increase in proportion of the S type cells. This suggests that S type motoneurons at ES are the surviving motoneurons that reduce their soma size.
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Immunohistochemistry markers used to label and group motoneurons into their respective types could change in the disease and confound our results. Thus, we used a two-step comparison approach to avoid this potential issue and confirm the above cell-type analysis. We first co-labelled spinal motoneurons of WT mice using SK3 and MMP9, two selective immunohistochemical markers for S type (Deardorff et al. 2013 ) and fast-fatigable (FF) type (Kaplan et al. 2014; Leroy et al. 2014; Morisaki et al. 2016 ) motoneurons, respectively. This allowed us to identify soma size ranges for S and FF type motoneurons. We then applied these soma size ranges to WT and G93A data (shown in Figs 2-4 ) and compared the soma sizes of S versus FF motoneurons (Fig 9A-D) (Fig. 9E, 141 of 520 cells, or 27.12%). The histograms of all three motoneuron types from four adult (P120-P130) WT and non-transgenic (WT nt ) mice were found to be comparable (data not shown) and, accordingly, their data were combined into one histogram showing the normal distributions of the different motoneuron types in the adult mouse lumbar cord (Fig. 9F) . A cumulative frequency histogram showing the relative numbers of S, FR, and FF motoneurons is shown in Fig. 9G . Although significant overlap was observed among the different types, disease-resistant motoneurons (primarily S and FR types) were found to form the vast majority of cells in the 400-600 μm 2 range, whereas disease-vulnerable motoneurons (i.e. the FF type) form the majority of cells in the 1100+ μm 2 range. When these soma size ranges were compared between WT and G93A mice, the identified disease-resistant majority motoneurons showed statistically significant reductions in soma size at P10 and ES, but surprisingly no change in soma size at P30 and P90 (Fig. 9H, Table 7 ). In other words, disease-resistant motoneurons never showed any increase in their soma size throughout the disease, even at P10 and P30 when the overall motoneuron population exhibited an increase in soma size (Fig. 2) , indicating that the enlargement observed at P10 and P30 was driven primarily by disease-vulnerable motoneurons. Motoneuron ranges were identified from adult mice, but the lower end of the soma size ranges identified above were slightly lowered at P10 (Fig. 9H) , as motoneurons are smaller at the neonatal phase than in adulthood (Li et al. 2005) . Given that the number of motoneurons with soma size larger than 1100 μm 2 is generally small in WT (see Figs 3A-D and 4A-D) and becomes even smaller in the G93A group due to their death in the disease, the sample size of disease-vulnerable motoneurons was too small to allow for similar robust statistical analysis.
Altogether, the results of this two-stage, doubleimmunolabelling analysis (Fig. 9) , along with the cell-type immunohistochemical analysis conducted in the previous section (Fig. 8) , confirm that disease-resistant vs. disease-vulnerable motoneurons demonstrate a soma size plasticity differential in ALS.
Effect of soma size changes on motoneuron excitability
To assess the significance of the soma size increases reported in this study on the excitability of diseasevulnerable motoneurons, we used a previously published, anatomically detailed computational model of spinal α-motoneurons (Elbasiouny et al. 2005) . This model includes the somatic and dendritic voltage-gated ion channels known to mediate action potentials in spinal motoneurons and has been previously verified and extensively used to examine the firing behaviours and excitability of spinal motoneurons (Elbasiouny et al. 2005 (Elbasiouny et al. , 2006 Elbasiouny & Mushahwar, 2007a,b; Elbasiouny, 2014) . The size of the soma in this model is 1.21% of the total surface area of the motoneuron, which is within the normal range of soma size in motoneurons (mean of ß1.5%, range 0.98-1.99%, Cullheim et al. 1987a,b) . In these simulations, the soma size of the model motoneuron was increased and the net excitability (assessed from the gain and shape of the frequency-current (F-I) relationship) was measured in response to a somatic current ramp (Fig. 10) . The data in Table 1 show that soma size of disease-vulnerable motoneurons could increase by an average of 15.9% (with 95% confidence interval range between 12% and 20%), we therefore ran simulations in which the soma size was increased by 12%, 16% and 20% -in order to show the range of effect resulting from the changes we report here -and the F-I relationships were compared to the control condition (Fig. 10) . Our simulations show that increasing the soma size by these percentages results in large suppression of the motoneuron excitability. Specifically, the firing bistability and the motoneuron gain were significantly reduced (Fig. 10 , data on 12% increase not shown). The motoneuron gain was calculated from the slope of linear lines fitted to the ascending firing segment of the F-I relationship of each condition (r 2 values ranged between 0.988 and 0.998), and the slope reduction relative to control ranged between 16.4% and 21.3%.
Collectively, these results show that, even with the small proportion of the soma size relative to the motoneuron size, an increase in soma size by the percentages reported in the present study (12% to 20%) would have a significant impact on the excitability of disease-vulnerable motoneurons.
Discussion
The present study provides, for the first time, evidence of the existence of plastic changes in the soma size of spinal α-motoneurons throughout the different stages of ALS. WT and G93A mice. B, density of S-type and F-type α-motoneurons from P10 WT and G93A mice. C, proportions of S-type and F-type α-motoneurons from P10 WT and G93A mice (P10). D, mean largest cross-sectional areas of lumbar SK3 + (S-type) and SK3 − (F-type) α-motoneurons from ES G93A and age-matched WT mice. E, density of S-type and F-type α-motoneurons from ES G93A and age-matched WT mice. F, proportions of S-type and F-type α-motoneurons from ES G93A and age-matched WT mice. Density measurements are expressed as the ratio of the total number of α-motoneurons within a spinal cord slice divided by the thickness of the slice. Proportion measurements are taken as a percentage of the total number of α-motoneurons measured. Statistical significance indicated as follows: * P < 0.05, * * * * P < 0. These changes have a time-dependent pattern: Changes start as an early somatic enlargement, followed by no change around symptom onset and then by later somatic shrinkage at disease end-stage. We have also identified a proportional relationship between the vulnerability of α-motoneurons and their soma size plasticity. Specifically, disease-vulnerable motoneurons were found to increase their soma size. On the other hand, while disease-resistant motoneurons showed variable soma size changes (decreases or no change), increases in their soma size were not observed. This plasticity differential between disease-vulnerable and disease-resistant motoneurons was confirmed across spinal cord regions, genders and motoneuron types. Computer simulations showed that the measured increases in soma size have a profound impact on the excitability of disease-vulnerable motoneurons.
With this information, our study extends the theory on motoneuron size-based vulnerability to indicate that not only is the vulnerability of motoneurons proportional to their size, but it is also related to whether motoneurons change their size during disease states. These results provide insightful information on the cellular changes that disease-vulnerable and disease-resistant motoneurons experience during ALS and how they relate, and probably contribute, to cell survival.
Morphological changes of motoneurons in ALS
A number of studies have examined the early morphological changes that neonatal spinal motoneurons experience in several animal models of ALS; however, none of these studies noted somatic changes (Amendola & Durand, 2008; Filipchuk & Durand, 2012; Leroy et al. 2014) . This is probably due to the very small sample size and/or gender breakdowns these studies included compared to ours, given that they conducted full dendritic reconstructions. However, most of these studies showed early dendritic enlargement of neonatal SOD1 motoneurons relative to WT (Amendola & Durand, 2008; Filipchuk & Durand, 2012) , which is in line with our data indicating early cell size enlargement. When a larger sample size was considered, Shoenfeld et al. (2014) observed an increase in the soma size of G93A motoneurons at P30, in agreement with our data. Additionally, soma hypertrophy has been reported in motoneurons in young mutant mice from the Wobbler model of motoneuron disease (Duchen & Strich, 1968; Dockery et al. 1997; Blondet et al. 2002) .
Disease-vulnerable motoneurons: somatic enlargement
Intriguingly, we note that the early somatic enlargement at P10 and P30 is specific to F-type, but not S-type, motoneurons, without any evidence of cell death at that time. This suggests that somatic enlargement might be a mechanism by which the intrinsic excitability of F-type motoneurons is regulated. An increase in soma size would have a large effect on the firing capacity of these cells as we have shown in our simulations, and this might be necessary to restore their firing behaviour during pathogenic states. Interestingly, it is also conceivable that the increase in size can damage the motoneuron by contributing to metabolic stress and energetic overload, exacerbating degenerative processes (Le Masson et al. 2014) . Furthermore, there is recent evidence that an increased motoneuron size might be a result of swelling due to an excessive influx of calcium ions (Porseva et al. 2017) . Given that calcium buffering capacity and mitochondrial dysfunction are thought to be major risk factors in motoneuron degeneration (von Lewinski & Keller, 2005) , one can speculate that swelling might thus contribute to calcium-related pathogenesis. Importantly, S-type motoneurons do not appear to use the mechanism of somatic enlargement in regulating their excitability early in the disease. This indicates a key difference in how these cells regulate their excitability -and probably arises from differences in intrinsic excitability properties.
Disease-resistant motoneurons: shrinkage or no change in soma size?
Our data have consistently shown that disease-resistant motoneurons do not exhibit an increase in soma size throughout the disease process. Interestingly, there were instances in which they exhibited no change (e.g. SK3+ motoneurons at P10 in Fig. 8A , and disease-resistant motoneurons at P30 and P90 in Fig. 9H ) or a decrease (e.g. cervical motoneurons in Fig. 6A , female motoneurons in Fig. 7A , SK3+ motoneurons at ES in Fig. 8D , and disease-resistant motoneurons at P10 and ES in Fig. 9H ) in soma size. We did observe a rightward shift in all motoneurons at P30 in Fig. 3D , suggesting that all motoneurons increased in size at this time point. However, when we restricted the analysis to the disease-resistant population at P30, we did not observe any changes in soma size (Fig. 9H) . These data could indicate that disease-resistant motoneurons are variable in soma size response to disease, or this inconsistency could be due to limitations of our size analysis. Thus, additional investigation is warranted at these earlier time points in order to better elucidate soma size plasticity within disease-resistant motoneurons. At the late disease stage, we found evidence of motoneuron shrinkage, which is also supported by the literature (e.g. SK3+ motoneurons at ES in Fig. 8D ). Motoneuron shrinkage has been reported both in post-mortem tissue from ALS patients (Kiernan & Hudson, 1991) and in late stages of disease pathogenesis in other mouse models of ALS (Dockery et al. 1997; Blondet et al. 2002) . In late disease stages, it has been largely assumed that cell death of larger motoneurons underlies this decrease in soma size. However, mounting evidence shows that motoneuron shrinkage is not necessarily linked to cell death. For instance, a study of late-stage facial motoneurons from the G93A and pmn mouse models of ALS showed evidence of shrinking in these two models, without any evidence of cell death (Haenggeli & Kato, 2002) . Our finding that S-type motoneurons have a reduced soma size, even in the absence of evidence of a reduction in their number (e.g. SK3+ motoneuron density in Fig. 8E ), supports the theory of shrinkage without, or before, cell death and warrants further investigation.
Motoneuron soma size changes: disease versus compensatory mechanism?
The time-dependent pattern of soma size changes during disease progression and the relationship between the vulnerability of α-motoneurons and their soma size plasticity together suggest that soma size changes are most likely not a disease mechanism. Instead, they appear to be among the compensatory mechanisms by which the motoneuron regulates its excitability and metabolic/energetic loads in order to preserve its signalling function in disease conditions. This fluctuation in soma size changes during disease progression is in agreement with the predictions of a dynamic meta-analysis examining the underlying pathology of ALS, which predicted unstable fluctuations in motoneuron cellular properties prior to cell death resulting from the dynamic interactions between disease and compensatory mechanisms (Mitchell & Lee, 2012) .
Motoneuron size plasticity in ALS: effect of gender
One important finding that we observed from our study was that not all motoneurons responded to the disease in the same way with regard to the changes in their soma size. For example, neonatal wild-type motoneurons from male and female mice were similar in size, but had opposite soma size changes during disease (enlargement in males and shrinkage in females). A recent study has shown that adult medial gastrocnemius-innervating motoneurons in male rats have a larger soma size than their female counterparts (Mierzejewska-Krzyzowska et al. 2014) . Thus, it appears that gender-based soma size differences in motoneuron populations do occur, but might happen later in normal maturation. An important question to address, then, is why there is a difference between male and female mutant motoneurons at this early neonatal time point.
It has been suggested that there is a critical period during the first two weeks of rodent development where hormonal changes influence motoneuron soma size drastically (Breedlove & Arnold, 1983; Lee et al. 1989; Varela et al. 2000) . For example, testosterone has been shown to increase motoneuron soma size (Kurz et al. 1986; Lee et al. 1989; Araki et al. 1991) . This testosteronemediated soma size increase has been shown to be preventable by the effect of neurotrophic factors (Varela et al. 2000) . In addition, decreased thyroid hormone has been associated with a decrease in motoneuron soma size (Bakels et al. 1998) . Interestingly, it has been postulated that prenatal testosterone levels are heightened in both male and female ALS patients (Vivekananda et al. 2011) . Thus, it is conceivable that the difference in soma size changes might be due to gender-related differences in hormone modulation in ALS, as males are disproportionally affected by the disease (McCombe & Henderson, 2010) . Female G93A rodents are also thought to show a later disease onset to males (Veldink et al. 2003; Suzuki et al. 2007) . Interestingly, Shoenfeld and colleagues observed an enlargement in soma size only in male but not female adult G93A motoneurons at a different time point (Shoenfeld et al. 2014) . It would be important to examine muscle-specific motoneuron groups separately (sexually dimorphic nuclei vs. other motoneurons) in male and female mice to better understand the nature of these differences.
Motoneuron size plasticity in ALS: effect of spinal cord region
There is a gradient of vulnerability among spinal motoneurons. In the G93A model, impairments in motor behaviours mediated by lumbar motoneurons emerge first, followed by tail impairments, which are mediated by sacral motoneurons (Alves et al. 2011) . Respiratory failure, which results from the death of cervical motoneurons, occurs later in the disease (Llado et al. 2006; Smittkamp et al. 2010) . As to what could explain this gradient of vulnerability, there is evidence that the populations of motoneurons in the C2-C5 region (which innervate the forelimbs, shoulders and diaphragm) appear not to accumulate SOD1 aggregates like their lumbar counterparts in mutant SOD1 mice (Turner et al. 2003) and that the motor nerves and muscles of the forelimbs and diaphragm are relatively preserved until late disease pathogenesis (Llado et al. 2006; Smittkamp et al. 2010) . In addition, the rodent diaphragm is thought to be predominantly composed of S-and FR-type fibres (of medium size and contractility speed) (Prakash et al. 2000) , and thus might not be innervated by as many disease-vulnerable motoneurons.
Thus, we predicted that the enlargement we saw in lumbar motoneurons would not occur in the sacral and cervical motoneurons. Interestingly, not only did we observe that cervical motoneurons were not enlarged, but also noted that they were significantly smaller at P30. Neurodegeneration begins before P40 in the spinal cord (Hegedus et al. 2007 (Hegedus et al. , 2008 ; thus cell death is likely not to be a factor this early in these mice, suggesting shrinkage of the cervical motoneuron soma as the most likely explanation. We also noted that WT and G93A cervical motoneurons appeared to be smaller than their lumbar counterparts, suggesting that there is a regional effect on motoneuron soma size. There are many possibilities that might explain this type of region-specific soma size plasticity: differences in intrinsic properties and synaptic coverage, local glial environment, and neuromuscular conditions. Additional studies exploring the relationships of these properties to soma size plasticity will be useful.
Methodological considerations
There are a few points to clarify regarding the apparent discrepancy in the literature on motoneuron soma size changes in ALS. First, many studies have grouped cells from mice of different genders or from different spinal cord regions (Amendola & Durand, 2008; Leroy et al. 2014; Shoenfeld et al. 2014 ) and this could have vastly changed the distribution and observation of changes. An apparent discrepancy in results between our study and prior studies can be addressed simply by taking gender separation (Amendola & Durand, 2008; Leroy et al. 2014) or spinal cord region separation (Shoenfeld et al. 2014) into account.
Second, while some studies used cell size as a criterion to identify α-motoneurons (Shoenfeld et al. 2014) , we employed previously identified α-motoneuron labelling markers to clearly delineate these cells (Figs 8 and 9) . This allowed us to minimize any additional source of identification error. In addition, we used type identification, which is critical as our data clearly delineates a significant overlap in motoneuron soma size between the different motoneuron types. In addition, this immunolabelling is particularly important in the investigation of soma size in ALS, where the size ranges of α-motoneurons might have shifted in the disease (as we observed throughout the different stages of disease pathogenesis). Additionally, we compared soma size ranges in WT animals, identified by immunohistochemical markers of specific motoneuron types. The two-stage approach that we used does not rely on the direct use of immunohistochemical markers in the disease; therefore, its results would not be affected by any potential changes to immunohistochemical markers in the disease, verifying our direct immunolabelling data.
Conclusion
In conclusion, we observed several plastic changes in the soma size of spinal motoneurons throughout the lifespan of the mutant SOD1-G93A mouse. We also provide evidence that the vulnerability of the α-motoneuron is related to these changes, such that disease-vulnerable motoneurons consistently exhibit increased soma sizes, whereas disease-resistant motoneurons do not. We confirmed this pattern across spinal cord regions, genders and motoneuron types. We also demonstrated via computer simulations that the measured increases in soma size have a profound impact on the excitability of disease-vulnerable and disease-resistant motoneurons. Our findings therefore extend the theory of motoneuron size-based vulnerability in ALS, in that large, disease-vulnerable motoneurons consistently increase soma size whereas small, disease-resistant motoneurons do not. They also support the notion that initial motoneuron size influences the cell's response and its fate during disease pathogenesis. These results provide insights on the pathophysiological significance of motoneuron soma size in ALS, and how it relates to cell survival. These data are expected to be informative to efforts in identifying mechanisms of ALS pathogenesis as well as potential avenues for therapies to prolong motoneuron life and function.
